Table 6.

Immunophenotype of the neoplastic cells in the 115 LRCHD cases as well as in the observed growth patterns and association with EBV infection

AntigenAll LRCHD cases (n = 115) positive findingsNodular LRCHD cases (n = 80) positive findingsInterfollicular and diffuse LRCHD cases (n = 35) positive findings
No.%No.%No.%
CD20 37 32 26 32.5 11 31 
CD79a 15 13 8.7 
J-chain 
CD30 107 98 74 92.5 32 91 
CD15 85 74 65 81 25 71 
EMA 2.5 11 
EBER-transcripts 46 47 29 41 17 61 
AntigenAll LRCHD cases (n = 115) positive findingsNodular LRCHD cases (n = 80) positive findingsInterfollicular and diffuse LRCHD cases (n = 35) positive findings
No.%No.%No.%
CD20 37 32 26 32.5 11 31 
CD79a 15 13 8.7 
J-chain 
CD30 107 98 74 92.5 32 91 
CD15 85 74 65 81 25 71 
EMA 2.5 11 
EBER-transcripts 46 47 29 41 17 61 

LRCHD, lymphocyte-rich classical Hodgkin disease; EMA, epithelial membrane antigen; EBER, EBV-encoded RNA.

The percentages have been calculated from assessable cases.